- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | CDMO Samsung Bio wins temporary reprieve from strike threat after Seoul court ruling | ||
| Di | Antheia lands $80M conditional loan from Trump administration to onshore drug manufacturing | ||
| Di | Cosette lands FDA approval for Evoxac liquid in Sjögren's disease | ||
| Di | AbbVie hits the gas on immunology awareness with McLaren F1 pact | ||
| Di | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| Di | Amgen, AZ dive deep into Tezspire's Dupixent-challenging victory in EoE phase 3 | ||
| 19.10. | GSK's Jemperli scores FDA approval in rectal cancer, backed by high complete response rate | ||
| 19.10. | EyePoint cuts headcount, shifts priorities after another Duravyu AMD miss | ||
| 19.10. | Roche pauses future Germany investments, joining growing pharma chorus of pullbacks | ||
| 19.10. | Novartis pauses midstage Fabhalta trial in lupus nephritis-but efficacy, safety not at play | ||
| 19.10. | Eli Lilly's Omvoh takes phase 3 win in pediatric UC, fueling expansion ambitions | ||
| 19.10. | The Next Chapter for AI in Clinical Trials | ||
| 19.10. | Closing the gap between approval and treatment | ||
| 16.10. | The Oral GLP-1 Tracker: Foundayo, Wegovy pill undergo minor fluctuations | ||
| 16.10. | Trump's pharma holdings surged as drugmakers benefited from Medicare price negotiation carveouts, Democrats allege | ||
| 16.10. | Why Are 53% of Phase 2 and 3 Trials Delayed? A Redesign Is Overdue | ||
| 16.10. | Sanofi cycles deeper into sports marketing niche as Tour de France partner | ||
| 16.10. | Lilly's obesity pill, RevMed's pancreatic cancer breakthrough among slew of CHMP endorsements in Europe | ||
| 16.10. | Inside Teva's Weltruza launch and Novo's GLP-1 strategy | ||
| 16.10. | Roche makes class-first push into thyroid eye disease with new FDA nod for Enspryng | ||
| 16.10. | Fierce Pharma Asia-Roche's $1.2B obesity deal; Asahi Kasei's FDA nod; Verastem's KRAS boon | ||
| 15.10. | Kindeva lands $226M defense contract to supply nerve agent antidote in US | ||
| 15.10. | Par Health recalls 22 lots of IV blood thinner, its 3rd US product pull in a month | ||
| 15.10. | With new Omvoh analyses, Lilly argues 'higher bar' for IBD treatment is within reach | ||
| 15.10. | Isotope supplier NorthStar continues rise with partnership to tee up China radiopharmaceutical filings |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.